SCHEMBL1004745

SCHEMBL1004745

CCCCCCCC/C=C\CCCCCCCC(=O)C(O)C(CO)OC(C)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 2/20 0.53
DGKA P23743 1/20 0.51
PRKCE Q02156 1/20 0.49
PRKCQ Q04759 1/20 0.49
PRKCD Q05655 1/20 0.49
FAAH O00519 3/20 0.47
TERT O14746 3/20 0.46
PTPN1 P18031 3/20 0.46
PPARG P37231 3/20 0.46
PPARD Q03181 3/20 0.46
PPARA Q07869 3/20 0.46
CYP1A2 P05177 2/20 0.46
MAPT P10636 2/20 0.46
CYP2C19 P33261 2/20 0.46
BLM P54132 2/20 0.46
HSD17B10 Q99714 2/20 0.46
FABP4 P15090 2/20 0.46
KMT2A Q03164 2/20 0.46
GMNN O75496 1/20 0.46
USP2 O75604 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL438671 1.00 PRKCA (0.53) PRKCADGKAPRKCEPRKCQPRKCD
SCHEMBL9054604 0.92 PRKCA (0.50) PRKCAMAPTKMT2ALMNADUSP3
SCHEMBL9055070 0.92 PRKCA (0.50) PRKCAMAPTKMT2ALMNADUSP3
SCHEMBL4964792 0.89 PRKCA (0.59) PRKCADGKAPRKCEPRKCQPRKCD
SCHEMBL9055293 0.89 PRKCA (0.59) PRKCADGKAPRKCEPRKCQPRKCD
SCHEMBL9055938 0.89 PRKCA (0.59) PRKCADGKAPRKCEPRKCQPRKCD
SCHEMBL1666730 0.89 PRKCA (0.59) PRKCADGKAPRKCEPRKCQPRKCD
SCHEMBL9057567 0.89 PRKCA (0.59) PRKCADGKAPRKCEPRKCQPRKCD
SCHEMBL6252306 0.89 PRKCA (0.59) PRKCADGKAPRKCEPRKCQPRKCD
SCHEMBL8369299 0.88 PRKCA (0.54) PRKCADGKAPRKCEPRKCQPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011011065-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2011-01-27 WO claimed
WO-1997004761-A1 METHODS AND COMPOSITIONS FOR TREATING CELL PROLIFERATIVE DISORDERS TRUSTEES OF BOSTON UNIVERSITY (US) 1997-02-13 WO claimed
EP-0706369-A1 STIMULATION OF TANNING BY DNA FRAGMENTS TRUSTEES OF BOSTON UNIVERSITY (US) 1996-04-17 EP claimed
WO-1996009810-A1 METHODS FOR ENHANCING MELANIN SYNTHESIS IN MELANOCYTES USING DIACYLGLYCEROLS AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 1996-04-04 WO claimed
EP-0655907-A1 USE OF DIACYLOLYCEROLS FOR INCREASING THE MELANIN CONTENT IN MELANOCYTES TRUSTEES OF BOSTON UNIVERSITY (US) 1995-06-07 EP claimed
WO-1995001773-A9 STIMULATION OF TANNING BY DNA FRAGMENTS 1995-02-16 WO claimed
WO-1995001773-A1 STIMULATION OF TANNING BY DNA FRAGMENTS TRUSTEES OF BOSTON UNIVERSITY (US) 1995-01-19 WO claimed
WO-1994004122-A2 USE OF DIACYLGLYCEROLS FOR INCREASING THE MELANIN CONTENT IN MELANOCYTES TRUSTEES OF BOSTON UNIVERSITY (US) 1994-03-03 WO claimed
EP-3501519-B1 BRYOSTATIN 1 FOR USE IN TREATING IGE MEDIATED ALLERGIC DISEASES NATIONAL UNIV CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY (JP) 2024-11-20 EP disclosed
WO-2023025899-A2 DELIVERY SYSTEM FOR TARGETING GENES OF THE INTERFERON PATHWAY TRANSGENE (FR) 2023-03-02 WO disclosed
WO-2020225085-A1 MEDIUM FOR GROWTH OF ORGANOIDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2020-11-12 WO disclosed
EP-2549980-A2 REVERSE MICELLE SYSTEM COMPRISING NUCLEIC ACIDS AND USE THEREOF Medesis Pharma (FR) 2013-01-30 EP disclosed
WO-2011117334-A2 REVERSE MICELLE SYSTEM COMPRISING NUCLEIC ACIDS AND USE THEREOF MEDESIS PHARMA (FR) 2011-09-29 WO disclosed
WO-2011011065-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2011-01-27 WO disclosed
WO-1994014065-A1 METHODS FOR IDENTIFYING AND USING IMMUNOSUPPRESSANT COMPOUNDS DANA-FARBER CANCER INSTITUTE, INC. (US) 1994-06-23 WO disclosed
WO-1994004122-A2 USE OF DIACYLGLYCEROLS FOR INCREASING THE MELANIN CONTENT IN MELANOCYTES TRUSTEES OF BOSTON UNIVERSITY (US) 1994-03-03 WO disclosed
WO-1992017151-A2 METHOD OF ADMINISTERING DRUGS THROUGH MODIFICATION OF EPITHELIAL TIGHT JUNCTIONS BY TUMOR NECROSIS FACTOR LANKENAU MEDICAL RESEARCH CENTER (US) 1992-10-15 WO disclosed
EP-0362278-A4 AUTOCRINE MOTILITY FACTORS IN CANCER DIAGNOSIS AND MANAGEMENT. US HEALTH (US) 1990-05-14 EP disclosed
EP-0362278-A1 AUTOCRINE MOTILITY FACTORS IN CANCER DIAGNOSIS AND MANAGEMENT THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) 1990-04-11 EP disclosed
WO-1988009797-A1 AUTOCRINE MOTILITY FACTORS IN CANCER DIAGNOSIS AND MANAGEMENT THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) 1988-12-15 WO disclosed